Skip to main
CRVO
CRVO logo

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc. reported a total operating expense of $8.4 million, with research and development costs indicating a strong commitment to advancing its product candidate, Neflamapimod, targeted at age-related neurologic disorders. The clinical results demonstrated significant reductions in plasma GFAP and meaningful improvements in key biomarker endpoints, reinforcing the drug's potential to combat neuroinflammation and synaptic dysfunction effectively. Additionally, favorable safety data and pronounced efficacy in patients without Alzheimer’s co-pathology suggest a robust foundation for advancing into Phase 3 trials, indicating a promising outlook for the company’s future development trajectory.

Bears say

CervoMed Inc reported a net loss of $7.7 million, translating to a loss of $0.84 per share, which raises concerns regarding the company's financial viability given the high operational costs associated with clinical trials. Additionally, while patients in Batch B showed reduced worsening in cognitive decline metrics and improvements versus placebo, these clinical indicators may not sufficiently address the overall financial sustainability and market confidence in the product candidate, Neflamapimod. The modest income contribution of $0.3 million indicates that revenue generation remains weak, further complicating the company's outlook amidst ongoing financial losses.

CervoMed Inc (CRVO) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 7 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.